Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 10
2012 24
2013 31
2014 34
2015 64
2016 48
2017 73
2018 92
2019 91
2020 56
2021 33
2022 6
2023 3
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

508 results

Results by year

Filters applied: . Clear all
Page 1
CTLA-4: a moving target in immunotherapy.
Rowshanravan B, Halliday N, Sansom DM. Rowshanravan B, et al. Blood. 2018 Jan 4;131(1):58-67. doi: 10.1182/blood-2017-06-741033. Epub 2017 Nov 8. Blood. 2018. PMID: 29118008 Free PMC article. Review.
Cancer immunotherapy using checkpoint blockade.
Ribas A, Wolchok JD. Ribas A, et al. Science. 2018 Mar 23;359(6382):1350-1355. doi: 10.1126/science.aar4060. Epub 2018 Mar 22. Science. 2018. PMID: 29567705 Free PMC article. Review.
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L. Vétizou M, et al. Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5. Science. 2015. PMID: 26541610 Free PMC article.
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RPM, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Silva IPD, Batten M, Scolyer RA, Long GV, Wilmott JS. Gide TN, et al. Cancer Cell. 2019 Feb 11;35(2):238-255.e6. doi: 10.1016/j.ccell.2019.01.003. Cancer Cell. 2019. PMID: 30753825 Free article.
Immune Checkpoint Inhibitors.
Haanen JB, Robert C. Haanen JB, et al. Prog Tumor Res. 2015;42:55-66. doi: 10.1159/000437178. Epub 2015 Sep 4. Prog Tumor Res. 2015. PMID: 26382943 Review.
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C. Boutros C, et al. Nat Rev Clin Oncol. 2016 Aug;13(8):473-86. doi: 10.1038/nrclinonc.2016.58. Epub 2016 May 4. Nat Rev Clin Oncol. 2016. PMID: 27141885 Review.
Immune Checkpoint Blockade in Cancer Therapy.
Postow MA, Callahan MK, Wolchok JD. Postow MA, et al. J Clin Oncol. 2015 Jun 10;33(17):1974-82. doi: 10.1200/JCO.2014.59.4358. Epub 2015 Jan 20. J Clin Oncol. 2015. PMID: 25605845 Free PMC article. Review.
508 results